1995
DOI: 10.1007/bf01778325
|View full text |Cite
|
Sign up to set email alerts
|

Comparison of effects of sirolimus on cytokine dependent and cytokine independent proliferation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2004
2004
2006
2006

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 8 publications
0
1
0
Order By: Relevance
“…It has been shown that SRL can reduce the likelihood of metastasis by increasing the expression of E‐cadherin, which increases the binding affinity of tumor cells to each other (15). Regarding the antitumoral activity of SRL, it has been shown that SRL inhibits the proliferation of transformed cell lines of lymphoid, CNS, hepatic, melanocytic, osteoblastic, myogenic, renal, and connective tissue origin as well as proliferation of T and B cells transformed by HTLV‐1 and EBV (16). In experimental studies, it has been shown that SRL has antiproliferative effects on certain types of tumors like renal cell cancer, rhabdomyosarcoma, B‐ and T‐cell lymphoma, glioma, breast cancer, colon carcinoma, multiple myeloma, ovarian cancer, prostate cancer, bladder cell carcinoma, non‐small cell lung cancer, pancreatic cancer, melanoma and hepatocellular carcinoma and it also has antiangiogenic capability by which it could prevent tumor growth (4, 17).…”
Section: Sirolimus (Rapamune®)mentioning
confidence: 99%
“…It has been shown that SRL can reduce the likelihood of metastasis by increasing the expression of E‐cadherin, which increases the binding affinity of tumor cells to each other (15). Regarding the antitumoral activity of SRL, it has been shown that SRL inhibits the proliferation of transformed cell lines of lymphoid, CNS, hepatic, melanocytic, osteoblastic, myogenic, renal, and connective tissue origin as well as proliferation of T and B cells transformed by HTLV‐1 and EBV (16). In experimental studies, it has been shown that SRL has antiproliferative effects on certain types of tumors like renal cell cancer, rhabdomyosarcoma, B‐ and T‐cell lymphoma, glioma, breast cancer, colon carcinoma, multiple myeloma, ovarian cancer, prostate cancer, bladder cell carcinoma, non‐small cell lung cancer, pancreatic cancer, melanoma and hepatocellular carcinoma and it also has antiangiogenic capability by which it could prevent tumor growth (4, 17).…”
Section: Sirolimus (Rapamune®)mentioning
confidence: 99%